May 13, 2010 – The American Food and Drug Administration (FDA) posted yesterday the following Safety Information Text (italic): GlaxoSmithKline and FDA notified healthcare professionals of a new safety finding in patients with thrombocytopenia due to chronic liver disease treated …

Eltrombopag [Promacta]: Portal Venous System Thromboses in Study of Patients With Chronic Liver Disease Read more »